[1]张洪敏.纳洛酮联合醒脑静在COPD合并Ⅱ型呼吸衰竭中的疗效及对预后的影响[J].医学信息,2023,36(22):82-84,139.[doi:10.3969/j.issn.1006-1959.2023.22.017]
　ZHANG Hong-min.Effect of Naloxone Combined with Xingnaojing in COPD with Type Ⅱ Respiratory Failureand its Effect on Prognosis[J].Journal of Medical Information,2023,36(22):82-84,139.[doi:10.3969/j.issn.1006-1959.2023.22.017]
点击复制

纳洛酮联合醒脑静在COPD合并Ⅱ型呼吸衰竭中的疗效及对预后的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年22期
页码:
82-84,139
栏目:
论著
出版日期:
2023-11-15

文章信息/Info

Title:
Effect of Naloxone Combined with Xingnaojing in COPD with Type Ⅱ Respiratory Failureand its Effect on Prognosis
文章编号:
1006-1959（2023）22-0082-04
作者:
张洪敏
（天津市宝坻区人民医院急诊科，天津 301899）
Author(s):
ZHANG Hong-min
(Emergency Department of Baodi District People’s Hospital,Tianjin 301899,China)
关键词:
纳洛酮; 醒脑静; COPD; Ⅱ型呼吸衰竭
Keywords:
Naloxone; Xingnaojing; COPD; Type Ⅱ respiratory failure
分类号:
R563.8
DOI:
10.3969/j.issn.1006-1959.2023.22.017
文献标志码:
A
摘要:
目的 研究纳洛酮联合醒脑静在COPD合并Ⅱ型呼吸衰竭中的疗效及对预后的影响。方法 选取2021年1月-2022年6月我院诊治的100例COPD合并Ⅱ型呼吸衰竭患者为研究对象，采用随机数字表法分为对照组和观察组，各50例。对照组采用醒脑静治疗，观察组在对照组基础上给予纳洛酮治疗，比较两组临床疗效、心率和呼吸频率、动脉血气指标[血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）]、肺功能指标[一秒用力呼气容积（FEV1）、用力肺活量（FVC）、一秒率（FEV1/FVC）]、不良反应发生率。结果 观察组治疗总有效率为96.00%，高于对照组的82.00%（P＜0.05）；观察组治疗后心率、呼吸频率小于对照组（P＜0.05）；观察组治疗后PaO2高于对照组，PaCO2低于对照组（P＜0.05）；观察组治疗后FEV1、FVC、FEV1/FVC高于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 纳洛酮联合醒脑静在COPD合并Ⅱ型呼吸衰竭中的效果良好，可有效缓解呼吸衰竭症状显，改善改善肺功能、血气指标，且不增加不良反应发生几率。
Abstract:
Objective To study the effect of naloxone combined with Xingnaojing on COPD complicated with type Ⅱ respiratory failure and its effect on prognosis.Methods A total of 100 patients with COPD complicated with type Ⅱ respiratory failure diagnosed and treated in our hospital from January 2021 to June 2022 were selected as the research objects. They were divided into control group and observation group by random number table method, with 50 cases in each group. The control group was treated with Xingnaojing, and the observation group was treated with naloxone on the basis of the control group. The clinical efficacy, heart rate and respiratory rate, arterial blood gas indexes [blood oxygen partial pressure (PaO2), arterial blood carbon dioxide partial pressure (PaCO2)], lung function indexes [forced expiratory volume in one second (FEV1), forced vital capacity (FVC), one second rate (FEV1/FVC)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.00%, which was higher than 82.00% in the control group (P<0.05). The heart rate and respiratory rate of the observation group were lower than those of the control group after treatment(P<0.05). PaO2 in the observation group was higher than that in the control group, and PaCO2 was lower than that in the control group after treatment(P<0.05). FEV1, FVC and FEV1/FVC in the observation group were higher than those in the control group after treatment(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Naloxone combined with Xingnaojing has a good effect in COPD complicated with type Ⅱ respiratory failure, which can effectively alleviate the symptoms of respiratory failure, improve lung function and blood gas indexes, and does not increase the incidence of adverse reactions.

参考文献/References:

[1]邓桂胜,罗勇.无创正压通气联合纳洛酮治疗慢性阻塞性肺疾病急性加重期并发Ⅱ型呼吸衰竭的临床研究[J].海军医学杂志,2016,37(1):30-31,46.[2]邵伯云,周维华,朱伯金,等.无创呼吸机联合纳洛酮治疗慢性阻塞性肺疾病急性加重期合并Ⅱ型呼吸衰竭的疗效观察[J].疑难病杂志,2017,16(1):40-43.[3]郭海燕,林淑芳,梁彩霞,等.血清SP-D、PARC/CCL18水平与慢性阻塞性肺疾病严重程度关系[J].实用医学杂志,2016,32(6):936-938.[4]Gunen H,Kilinc O,Polatli M,et al.Modification of the GOLD recommendations for chronic obstructive pulmonary disease to broaden their usage in Turkey[J].Expert Rev Respir Med,2016,10(6):625-628.[5]王菲,李松.前列腺素E1联合瑞舒伐他汀在慢性阻塞性肺疾病合并肺动脉高压中应用对患者氧化应激反应、血管新生和NT-proBNP水平的影响[J].湖南师范大学学报(医学版),2020,17(2):152-156.[6]汤晓凤,刘旭春.孟鲁司特钠对慢性阻塞性肺疾病急性加重期患者炎症因子、肺功能的影响[J].川北医学院学报,2019,34(1):71-73.[7]汪智宝,刘涛.纳美芬与纳洛酮对新生儿急性呼吸窘迫综合征的治疗比较[J].临床肺科杂志,2016,21(4):764-765,773.[8]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[9]Hamai K,Iwamoto H,Ishikawa N,et al.Comparative Study of Circulating MMP-7,CCL18,KL-6,SP-A,and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis[J].Dis Markers,2016,2016:4759040.[10]何永鸿,王宋平.丙氨酸-谷氨酰胺肠外营养支持治疗慢性阻塞性肺病急性加重期合并Ⅱ型呼吸衰竭患者的临床效果观察[J].广西医学,2020,42(4):440-443.[11]陈芳,杜锦辉.机械通气辅以纳洛酮治疗慢性阻塞性肺疾病并呼吸衰竭疗效研究[J].陕西医学杂志,2020,49(4):466-469.[12]孟小蓉,杨娇,张磊.盐酸纳洛酮在慢性阻塞性肺疾病合并呼吸衰竭治疗中的应用研究[J].实用医院临床杂志,2018,15(4):105-108.[13]李艳艳.纳洛酮联合沙丁胺醇对COPD合并呼吸衰竭患者IL-6、TNF-α和IL-8的影响[J].河北医药,2018,40(7):1068-1070.[14]Górecka D,Jassem E,Pierzcha?覥a W,et al.Recommendations of the Polish Society of Lung Diseases for diagnosis and treatment of chronic obstructive pulmonary disease (COPD).Pneumonol Alergol Pol,2012,80(3):220-254.[15]孙月玲,林森,邓武兴,等.纳美芬联合无创正压通气对AECOPD并发呼吸衰竭患者Th1、Th2、sTREM-1的影响[J].中国老年学杂志,2018,38(11):2634-2637.[16]徐辉.醒脑静治疗慢性阻塞性肺疾病急性加重期呼吸衰竭的临床研究[J].中医学报,2011,26(6):652-654.[17]朱先锋.醒脑静注射液治疗慢性阻塞性肺疾病急性加重期呼吸衰竭临床研究[J].新中医,2020,52(17):61-63.[18]李艳艳.纳洛酮联合沙丁胺醇对COPD合并呼吸衰竭患者IL-6、TNF-α和IL-8的影响[J].河北医药,2018,40(7):1068-1070.[19]李静,林忠贤,周国红.氨茶碱联合布地奈德福莫特罗对AECOPD患者氧化应激及肺功能的影响[J].海南医学,2020,31(2):167-170.[20]和建武,郭春丽,程西安,等.无创通气模式下采用纳洛酮联合中药汤剂方对老年COPD合并Ⅱ型呼吸衰竭患者血气指标、肺功能及心理状态的影响[J].检验医学与临床,2022,19(13):1761-1765.

相似文献/References:

[1]王大建.呼吸兴奋剂（尼可刹米+洛贝林）联合纳洛酮与氟马西尼在重度安眠药物中毒抢救治疗中的效果观察[J].医学信息,2018,31(02):128.[doi:10.3969/j.issn.1006-1959.2018.02.047]
　WANG Da-jian.Curative Effect of Respiratory Stimulant(Nikethamide+Lobelin)Combined with Naloxone and Flumazenil in the Rescue Treatment of Severe Hypnotic Poisoning[J].Journal of Medical Information,2018,31(22):128.[doi:10.3969/j.issn.1006-1959.2018.02.047]
[2]李雨芹,黄顺贵,王思迅,等.醒脑静注射液辅助治疗血管性痴呆的疗效的Meta分析[J].医学信息,2018,31(11):84.[doi:10.3969/j.issn.1006-1959.2018.11.026]
　LI Yu-qin,HUANG Shun-gui,WANG Si-xun,et al.Meta Analysis of Efficacy of Xingnaojing Injection in Adjuvant Treatment of Vascular Dementia[J].Journal of Medical Information,2018,31(22):84.[doi:10.3969/j.issn.1006-1959.2018.11.026]
[3]刘永刚,张学勇.醒脑静联合盐酸纳洛酮治疗脑出血后昏迷患者的疗效分析[J].医学信息,2019,32(06):157.[doi:10.3969/j.issn.1006-1959.2019.06.050]
　LIU Yong-gang,ZHANG Xue-yong.Therapeutic Effect of Xingnaojing Combined with Naloxone Hydrochloride on Patients with Coma after Cerebral Hemorrhage[J].Journal of Medical Information,2019,32(22):157.[doi:10.3969/j.issn.1006-1959.2019.06.050]
[4]刘伟娜.纳洛酮联合亚低温疗法基础治疗脑出血的临床效果观察[J].医学信息,2019,32(07):153.[doi:10.3969/j.issn.1006-1959.2019.07.047]
　LIU Wei-na.Clinical Observation of Naloxone Combined with Mild Hypothermia Therapy for Cerebral Hemorrhage[J].Journal of Medical Information,2019,32(22):153.[doi:10.3969/j.issn.1006-1959.2019.07.047]
[5]李继荣,王志坚,李三清,等.氟马西尼及纳洛酮治疗肝昏迷的疗效比较[J].医学信息,2023,36(09):120.[doi:10.3969/j.issn.1006-1959.2023.09.024]
　LI Ji-rong,WANG Zhi-jian,LI San-qing,et al.Efficacy Comparison of Flumazenil and Naloxone in the Treatment of Hepatic Coma[J].Journal of Medical Information,2023,36(22):120.[doi:10.3969/j.issn.1006-1959.2023.09.024]

更新日期/Last Update: 1900-01-01